Form 4: Doi Acquires Quest Diagnostics Stock

Tracey Doi, a Director at Quest Diagnostics, acquired 1,142 shares of common stock on May 20, 2026, as part of a restricted stock unit award.

Summary

• Tracey Doi, a Director of Quest Diagnostics Inc., acquired 1,142 shares of common stock on May 20, 2026.
• The acquisition was made under a restricted stock unit award.
• Following this transaction, Doi beneficially owns 7,748 shares of common stock directly.
• The filing also notes that the amount includes shares acquired via dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider buying can be positive, this specific transaction is an award of restricted stock units and dividend reinvestment, which is a routine part of director compensation and not necessarily indicative of a strong conviction buy.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 1,142 shares directly by a director increases their direct ownership stake.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by directors, are common events in the healthcare diagnostics sector. Such transactions often reflect a belief in the company's ongoing performance and strategic direction.

Stakeholder Impact

• Shareholders: May view director stock acquisition positively as a sign of confidence, though the nature of the award (RSU) makes it less of a market signal than an open-market purchase.
• Management: The transaction is part of standard compensation for directors.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Quest Diagnostics, DGX, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, Director, Beneficial Ownership